The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw

Clinical Biochemistry

Volumn 42, Issue 10-11, 2009, Pages 1194-1196

  Don Wauchope, Andrew C ^a   Cole, David E C ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bisphosphonate; Bone turnover marker; Dental surgery; Osteonecrosis of the jaw

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE;

ARTICLE; DENTAL SURGERY; DIAGNOSTIC TEST; DRUG EXPOSURE; DRUG MEGADOSE; HUMAN; JAW OSTEONECROSIS; LOW DRUG DOSE; OSTEOLYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

BIOLOGICAL MARKERS; BONE RESORPTION; DIPHOSPHONATES; HUMANS; JAW DISEASES; ORAL SURGICAL PROCEDURES; OSTEONECROSIS;

EID: 67349161445     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.02.014     Document Type: Article

References (16)

1. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J. Bone Miner. Res. 22 (2007) 1479-1491
2. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 65 (2007) 369-376
3. Lam D.K., Sandor G.K., Holmes H.I., Evans A.W., and Clokie C.M. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J. Can. Dent. Assoc. 73 (2007) 417-422
4. Khosla S., Burr D., Cauley J., et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum ctx testing, prevention, and treatment. J. Oral Maxillofac. Surg. 66 (2008) 1320-1321
5. Pazianas M., Miller P., Blumentals W.A., Bernal M., and Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin. Ther. 29 (2007) 1548-1558
6. Khan A.A., Sandor G.K., Dore E., et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J. Rheumatol. 35 (2008) 1391-1397
7. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J. Oral. Maxillofac. Surg. 65 (2007) 415-423
8. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23 (2005) 8580-8587
9. Murad O.M., Arora S., Farag A.F., and Guber H.A. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr. Pract. 13 (2007) 232-238
10. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum ctx testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65 (2007) 2397-2410
11. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63 (2005) 1567-1575
12. Bagan J.V., Jimenez Y., Gomez D., Sirera R., Poveda R., and Scully C. Collagen telopeptide (serum ctx) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol. 44 (2008) 1088-1089
13. Lehrer S., Montazem A., Ramanathan L., et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 106 (2008) 389-391
14. Brown J., Albert C., Nassar B., et al. Bone turnover markers in the management of postmenopausal osteoporosis: a Canadian perspective. Clin Biochem 42 (2009) 929-942
15. Rosen C.J., Hochberg M.C., Bonnick S.L., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20 (2005) 141-151
16. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner 2009; in press. doi:10.1359/JBMR.090203.